Prestige Consumer Healthc... (PBH)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
76.09
0.31 (0.41%)
At close: Jan 15, 2025, 9:35 AM
Prestige Consumer Healthcare Inc. Revenue Breakdown
Quarter | Sep 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Analgesics Revenue | 28.22M | 55.82M | 30.27M | 31.36M | 28.50M | 29.07M | 28.77M | 29.46M | 28.76M | 28.41M | 31.45M | 29.39M | 29.80M | 30.10M | 32.88M | 30.54M | 28.65M | 88.56M | 30.90M | 30.38M | 27.38M | 28.84M | 29.86M | 25.70M |
Analgesics Revenue Growth | -49.44% | +84.44% | -3.49% | +10.02% | -1.96% | +1.07% | -2.36% | +2.43% | +1.22% | -9.66% | +7.03% | -1.38% | -1.01% | -8.46% | +7.68% | +6.58% | -67.65% | +186.57% | +1.72% | +10.97% | -5.08% | -3.42% | +16.22% | n/a |
Cough and Cold Revenue | 29.27M | 52.61M | 33.17M | 33.23M | 29.96M | 26.32M | 22.72M | 31.72M | 26.23M | 21.39M | 33.09M | 26.23M | 22.02M | 26.19M | 33.97M | 26.27M | 22.36M | 82.41M | 34.16M | 29.20M | 24.27M | 35.76M | 30.23M | 24.80M |
Cough and Cold Revenue Growth | -44.36% | +58.60% | -0.18% | +10.91% | +13.84% | +15.83% | -28.37% | +20.95% | +22.64% | -35.38% | +26.18% | +19.08% | -15.91% | -22.90% | +29.33% | +17.47% | -72.87% | +141.23% | +16.99% | +20.35% | -32.14% | +18.28% | +21.90% | n/a |
Dermatologicals Revenue | 35.85M | 66.85M | 27.77M | 34.49M | 23.88M | 28.61M | 26.43M | 21.98M | 25.94M | 25.65M | 23.30M | 26.34M | 24.63M | 20.04M | 20.43M | 23.52M | 23.37M | 64.82M | 20.26M | 23.81M | 20.63M | 18.23M | 18.15M | 11.56M |
Dermatologicals Revenue Growth | -46.36% | +140.73% | -19.48% | +44.39% | -16.53% | +8.28% | +20.25% | -15.28% | +1.13% | +10.11% | -11.57% | +6.95% | +22.93% | -1.90% | -13.15% | +0.64% | -63.95% | +219.95% | -14.91% | +15.41% | +13.14% | +0.48% | +56.97% | n/a |
Eye and Ear Care Revenue | 42.79M | 87.48M | 45.07M | 46.87M | 27.25M | 25.47M | 29.76M | 26.52M | 27.84M | 28.09M | 24.84M | 25.13M | 28.33M | 28.40M | 26.57M | 25.92M | 28.80M | 82.95M | 24.55M | 27.74M | 28.26M | 23.60M | 25.43M | 25.37M |
Eye and Ear Care Revenue Growth | -51.09% | +94.09% | -3.84% | +71.97% | +7.00% | -14.42% | +12.25% | -4.76% | -0.89% | +13.11% | -1.15% | -11.30% | -0.26% | +6.89% | +2.49% | -10.00% | -65.28% | +237.89% | -11.51% | -1.84% | +19.77% | -7.22% | +0.26% | n/a |
Gastrointestinal Revenue | 60.06M | 117.22M | 61.63M | 52.76M | 44.74M | 41.24M | 38.56M | 41.06M | 38.48M | 38.79M | 40.64M | 36.46M | 36.16M | 33.77M | 21.81M | 22.37M | 23.36M | 71.67M | 22.92M | 24.40M | 24.13M | 24.03M | 26.49M | 23.54M |
Gastrointestinal Revenue Growth | -48.76% | +90.21% | +16.80% | +17.93% | +8.49% | +6.96% | -6.09% | +6.70% | -0.80% | -4.56% | +11.47% | +0.83% | +7.08% | +54.85% | -2.49% | -4.25% | -67.40% | +212.72% | -6.09% | +1.14% | +0.40% | -9.29% | +12.57% | n/a |
Oral Care Revenue | 24.08M | 50.06M | 23.46M | 22.78M | 23.80M | 23.50M | 22.63M | 24.83M | 25.87M | 24.86M | 30.41M | 28.09M | 27.78M | 27.67M | 27.21M | 27.19M | 26.03M | 41.00M | 10.12M | 9.92M | 10.17M | 12.47M | 13.06M | 10.26M |
Oral Care Revenue Growth | -51.89% | +113.37% | +2.99% | -4.26% | +1.25% | +3.85% | -8.87% | -4.00% | +4.04% | -18.24% | +8.27% | +1.09% | +0.41% | +1.69% | +0.09% | +4.46% | -36.52% | +305.09% | +2.02% | -2.45% | -18.45% | -4.51% | +27.30% | n/a |
Other OTC Revenue | 3.16M | 6.17M | 3.11M | 2.75M | 1.29M | 1.26M | 1.29M | 1.59M | 1.35M | 1.24M | 1.63M | 1.28M | 1.25M | 1.41M | 1.39M | 1.55M | 1.49M | 4.54M | 1.56M | 1.50M | 1.42M | 1.48M | 1.93M | 2.94M |
Other OTC Revenue Growth | -48.85% | +98.52% | +13.14% | +112.95% | +2.22% | -2.17% | -19.12% | +17.89% | +9.38% | -24.20% | +27.10% | +2.97% | -11.43% | +1.51% | -10.34% | +4.03% | -67.24% | +190.96% | +3.65% | +6.06% | -4.25% | -23.05% | -34.51% | n/a |
Women's Health Revenue | 60.35M | 120.08M | 58.27M | 62.07M | 62.12M | 62.58M | 62.00M | 64.25M | 64.88M | 65.73M | 66.05M | 63.34M | 66.74M | 51.68M | 31.48M | 33.90M | 33.82M | 100.77M | 34.40M | 34.41M | 33.61M | 31.95M | 9.78M | n/a |
Women's Health Revenue Growth | -49.75% | +106.09% | -6.13% | -0.08% | -0.74% | +0.95% | -3.51% | -0.97% | -1.29% | -0.47% | +4.27% | -5.09% | +29.14% | +64.19% | -7.16% | +0.24% | -66.43% | +192.95% | -0.04% | +2.39% | +5.18% | +226.82% | n/a | n/a |
Revenue by Geography
Quarter | Mar 31, 2024 | Mar 31, 2017 | Mar 31, 2016 | Mar 31, 2015 |
---|---|---|---|---|
North American Otc Healthcare Revenue | 958.26M | 2.89B | 2.63B | 2.26B |
North American Otc Healthcare Revenue Growth | -66.81% | +9.62% | +16.72% | n/a |
Operating Expense Breakdown
Quarter | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selling, General, and Administrative Revenue | 67.48M | 68.28M | 63.98M | 65.47M | 66.10M | 63.92M | 58.53M | 56.96M | 70.26M | 66.67M | 64.75M | 66.22M | 72.98M | 61.91M | 60.24M | 59.48M | 58.73M | 47.68M | 63.75M | 54.87M | 61.18M | 56.51M | 55.73M | 54.99M | 61.08M | 61.05M | 157.13M | 57.04M | 60.76M | 57.28M | 70.21M | 52.81M | 47.39M | 47.09M | 46.78M | 48.07M | 44.35M | 44.01M | 43.05M |
Selling, General, and Administrative Revenue Growth | -1.17% | +6.71% | -2.27% | -0.95% | +3.41% | +9.20% | +2.77% | -18.93% | +5.39% | +2.97% | -2.23% | -9.26% | +17.88% | +2.77% | +1.28% | +1.27% | +23.16% | -25.20% | +16.19% | -10.32% | +8.27% | +1.39% | +1.35% | -9.97% | +0.04% | -61.15% | +175.47% | -6.11% | +6.07% | -18.42% | +32.94% | +11.45% | +0.63% | +0.66% | -2.68% | +8.38% | +0.78% | +2.23% | n/a |
Research and Development Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Research and Development Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales and Marketing Revenue | 41.41M | 39.37M | 37.52M | 39.47M | 40.10M | 36.23M | 30.87M | 30.42M | 43.82M | 39.95M | 36.94M | 40.24M | 40.73M | 39.44M | 36.42M | 38.08M | 38.34M | 27.75M | 40.17M | 33.56M | 38.67M | 34.80M | 34.43M | 34.50M | 37.04M | 37.11M | 35.32M | 35.84M | 39.19M | 36.94M | 41.45M | 30.68M | 28.59M | 27.64M | 26.55M | 29.93M | 27.89M | 26.42M | 25.37M |
Sales and Marketing Revenue Growth | +5.19% | +4.93% | -4.94% | -1.59% | +10.68% | +17.37% | +1.46% | -30.57% | +9.68% | +8.17% | -8.21% | -1.21% | +3.27% | +8.30% | -4.37% | -0.68% | +38.17% | -30.91% | +19.69% | -13.21% | +11.11% | +1.07% | -0.21% | -6.85% | -0.19% | +5.07% | -1.44% | -8.56% | +6.07% | -10.87% | +35.10% | +7.31% | +3.46% | +4.08% | -11.30% | +7.32% | +5.57% | +4.16% | n/a |